Aditxt, Inc. (ADTX)

Compare

4.5200

+0.0350

+(0.78%)

At close: 4:00:01 PM EDT

4.4600

-0.06

(-1.33%)

After hours: 4:41:26 PM EDT

Upcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection

MOUNTAIN VIEW, Calif., March 28, 2025--Aditxt, Inc. (NASDAQ: ADTX), ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that today’s Aditxt Weekly Update will focus on the recent acquisition of the CaSe Platform by its subsidiary, Pearsanta, Inc. ("Pearsanta"). The proprietary technology is based on adductomics and is designed to assess early DNA changes that may lead to mutations associated with cancer and other illnesses. The discussio

Business Wire 4 days ago

ADTX
+0.78%
Evofem Reports Fourth Consecutive Year of Net Sales Growth

Women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2024. Highlights include:

PR Newswire 8 days ago

EVFM

WINT

WINTW
Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk

MOUNTAIN VIEW, Calif., March 24, 2025--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has acquired key patents related to adductomics-based DNA damage detection, which it believes will further strengthen its position in the cancer prevention-focused diagnostic industry.

Business Wire 8 days ago

ADTX
+0.78%
Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update

Four new funding proposals, totalling US$117.5 million, have been submitted for reviewModifications received to U.S. Air Force Academy Cooperative AgreementOutside date for going-private transaction extended to March 31, 2025 HALIFAX, Nova Scotia, March 18, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that, the

GlobeNewswire 14 days ago

APLIF

ADTX
+0.78%
Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025

MOUNTAIN VIEW, Calif., March 17, 2025--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today provided a corporate update outlining recent achievements and strategic milestones across its subsidiaries and strategic acquisition initiatives. In addition, the Company will be launching Aditxt Weekly Updates, starting Friday March 21, 2025, and continuing throughout the second quarter of 2

Business Wire 15 days ago

ADTX
+0.78%
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025

MOUNTAIN VIEW, Calif., March 12, 2025--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, announced today that it will effect a 1-for-250 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on March 17, 2025, the Company’s common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by t

Business Wire 20 days ago

ADTX
+0.78%
Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.

MOUNTAIN VIEW, Calif., March 06, 2025--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today provided an update on its subsidiary, Adimune, Inc., ("Adimune") and its progress in advancing ADI-100, an investigational product candidate to be studied in patients with Psoriasis, Type I Diabetes (T1D) and Stiff Person Syndrome.

Business Wire 26 days ago

ADTX
+0.78%
Aditxt subsidiary Persanta engages Dominary Securities for IPO

The company states: “Aditxt (ADTX) announced that its subsidiary, Pearsanta has engaged Dominari Securities LLC as lead underwriter for Pearsanta’s planned initial public offering. The proposed IPO, advised by Dominari Securities, is intended to support Pearsanta’s U.S. and international commercial launch efforts and further advance its Mitomic(R) Technology platform for early cancer detection and diagnosis. Pearsanta is developing a non-invasive blood-based test designed to detect cancer at ear

TipRanks last month

ADTX
+0.78%
Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025

MOUNTAIN VIEW, Calif., February 21, 2025--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has engaged Dominari Securities LLC as lead underwriter for Pearsanta’s planned initial public offering (IPO). The proposed IPO, advised by Dominari Securities, is intended to support Pearsanta’s U.S. and international commercial launch efforts and

Business Wire last month

ADTX
+0.78%
Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time

MOUNTAIN VIEW, Calif., February 13, 2025--Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ: ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced that it will host a virtual Fireside Chat on Friday, February 21, 2025, at 11:30 AM Eastern Time. The event will feature Amro Albanna, CEO of Aditxt, who will provide updates on key corporate developments, including the status of current subsidiaries, potential transactions, and notable advancements

Business Wire last month

ADTX
+0.78%
Aditxt’s Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform

MOUNTAIN VIEW, Calif., January 13, 2025--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, is pleased to announce that its Board of Directors has authorized management to explore taking its subsidiary, Pearsanta, Inc. ("Pearsanta"), public via a proposed initial public offering ("IPO") in 2025. This decision aligns with Aditxt's mission to secure and develop transformative health innovations, positioning

Business Wire 2 months ago

ADTX
+0.78%
Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

MOUNTAIN VIEW, Calif., December 12, 2024--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Adimune, Inc. ("Adimune"), has successfully completed all preclinical efficacy and safety studies for its antigen-specific gene therapy, ADI-100. This achievement represents a major milestone as Adimune prepares to submit a Clinical Trial Application (CTA)/Investigational New Dr

Business Wire 3 months ago

APLIF

ADTX
+0.78%
EVFM
Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Court’s approval allows transaction with Aditxt to proceed, subject to other closing conditions HALIFAX, Nova Scotia, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, is pleased to announce receipt of the final order of the On

GlobeNewswire 4 months ago

APLIF

ADTX
+0.78%
Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced financial results for the third quarter and nine-month period ended September 30, 2024. Highlights include:

PR Newswire 4 months ago

EVFM

ADTX
+0.78%
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025

Overwhelming shareholder support in favour of take-private transaction with Aditxt Studies presented at IDWeek 2024™ demonstrate ATI-1701 provides full protection against lethal tularemia in animal models after one year Alignment with U.S. Food and Drug Administration on development requirements for ATI-1801 NDA Submission HALIFAX, Nova Scotia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on

GlobeNewswire 4 months ago

APLIF

ADTX
+0.78%
Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

MOUNTAIN VIEW, Calif., November 08, 2024--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today provided an update to its shareholders on the utilization of its Equity Line of Credit ("ELOC") and At-the-Market ("ATM") facility, as well as its outstanding number of shares.

Business Wire 4 months ago

APLIF

ADTX
+0.78%
EVFM
Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

MOUNTAIN VIEW, Calif., November 07, 2024--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target acquisition, Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) ("Appili"). Shareholders of Appili overwhelmingly voted in favor of a plan of arrangement for Aditxt to acquire all issued and outstanding Class A common shares of Appili. For additional information

Business Wire 4 months ago

APLIF

ADTX
+0.78%
Appili Therapeutics Announces Results of Special Meeting of Shareholders

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced the results from its special meeting of shareholders held earlier today (the “Meeting”). Shareholders of the Company (the “Shareholders”),

GlobeNewswire 4 months ago

APLIF

ADTX
+0.78%
Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

MOUNTAIN VIEW, Calif., November 06, 2024--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, announced today that its acquisition target, Evofem Biosciences, Inc. ("Evofem") (OTCQB: EVFM), has secured voting agreements with certain of its investors to ensure they will vote in favor of the merger proposal at Evofem’s upcoming Special Meeting of Stockholders (the "Special Meeting").

Business Wire 4 months ago

APLIF

ADTX
+0.78%
EVFM
Evofem Secures Investor Support for Proposed Merger through Voting Agreements

Evofem Biosciences, Inc. (OTCQB: EVFM) ("Evofem" or the "Company") today announced it has secured voting agreements with certain of its Series E-1 stockholders and convertible noteholders to ensure they will vote in favor of the proposed merger with Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt") subsidiary Adifem, Inc., under the Amended and Restated Merger Agreement, as amended (the "A&R Merger Agreement), at Evofem's upcoming Special Meeting of Stockholders (the "Meeting").

PR Newswire 4 months ago

EVFM

ADTX
+0.78%

Performance Overview

Return	ADTX	S&P 500 (^GSPC)
YTD	-90.48%	-4.23%
1-Year	-99.99%	+7.42%
3-Year	-100.00%	+23.92%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Aditxt, Inc. (ADTX)

Upcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection

Evofem Reports Fourth Consecutive Year of Net Sales Growth

Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk

Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update

Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025

Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.

Aditxt subsidiary Persanta engages Dominary Securities for IPO

Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025

Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time

Aditxt’s Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Appili Therapeutics Announces Results of Special Meeting of Shareholders

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

Evofem Secures Investor Support for Proposed Merger through Voting Agreements

Performance Overview